Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel

Journal of Family Planning and Reproductive Health Care

Volumn 37, Issue 3, 2011, Pages 132-135

  Heinemann Jr , Klaas ^a   Heinemann, Lothar A J ^a  

^a ZEG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; LEVONORGESTREL;

BODY MASS; DATA BASE; DEEP VEIN THROMBOSIS; DRUG INDUCED DISEASE; HUMAN; INCIDENCE; LUNG EMBOLISM; NOTE; ORAL CONTRACEPTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; UNITED KINGDOM; UNITED STATES; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, SYNTHETIC; FEMALE; HUMANS; LEVONORGESTREL; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 79961092762     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2011-14524     Document Type: Note

References (23)

1. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151.
2. Parkin L, Sharpies K, Hernandez RK, et al. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;342:d2139.
3. Grimes DA. Epidemiologic research using administrative databases: garbage in, garbage out. Obstet Gynecol 2010;116:1018-1019.
4. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care 2010;36:33-38.
5. Severinsen MT, Kristensen SR, Overvad K, et al. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol 2010;63:223-228.
6. Heinemann LA, Dinger JC, Assmann A, et al. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare". Contraception 2010;81:401-407.
7. Heinemann LAJ, Dinger JC. Range of published estimates of VTE incidence in young women. Contraception 2007;75:3328-3336.
8. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-354.
9. Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.
10. Schwarz T, Siegert G, Oertler W, et al. Venous thrombosis after long-haul flights. Arch Intern Med 2003;163:2759-2764.
11. Sheldon T. Dutch GPs warned against new contraceptive pill. BMJ 2002;324:869.
12. van Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003;326:257. (Pubitemid 36169591)
13. Pearce HM, Layton D, Wilton LV, et al. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. BrJ Clin Pharmacol 2005;60: 98-102. (Pubitemid 40942787)
14. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-146. (Pubitemid 27450823)
15. Suissa S, Spitzer WO, Rainville B, et al. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000;15:817-821. (Pubitemid 30192729)
16. van Hylckama Vlieg A, Heimerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.
17. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187-196.
18. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344: 1453-1457. (Pubitemid 24351698)
19. Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010;36:117-122.
20. Dinger J, Assmann A, Möhner S, et al. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German casecontrol study. J Fam Plann Reprod Health Care 2010;36: 123-129.
21. Seeger JD, Loughlin J, Eng PM, et al. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-593. (Pubitemid 47359582)
22. Heinemann K Jr. Problems associated with comprehensive detection/validation of unexpected ADRs in a population. PMR Newsletter 2010;5:1-3,9-10. http://www.prmnewsletter.org/file/ heinemann-2.pdf [accessed 12 May 2011].
23. Dunn N. Oral contraceptives and venous thromboembolism. BMJ 2009;339:b3164.